Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Xilio Therapeutics, Inc. (XLO)
Informatica Inc. (INFA)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

Absci Corporation (ABSI)

Sector - Healthcare

Price chart

-33.72%
Return from IPO

Company News

IPO Profile

About company

Company Logo
Their mission is to change the world, one protein at a time. They founded Absci with the goal of creating better medicines and helping them reach patients sooner. They recognized the extraordinary medical and economic potential of protein-based drugs (biologics), but also the significant challenges the biopharmaceutical industry faces to both discover novel biologics and generate cell lines to manufacture them at commercial scale. They built their technology to be that how. They believe they are replacing the fragmented steps and inefficiencies of the conventional biologic drug discovery and cell line development processes with their fully integrated, end-to-end platform designed to create new and better biologics and accelerate their advancement into clinical trials and ultimately into the marketplace where they can serve patients. Combining innovative approaches, including synthetic biology, high-throughput single-cell screening, and deep learning artificial intelligence (AI), they seek to identify optimal drug candidates by exploring expansive protein sequence solution spaces -- including considering sequences that nature's evolutionary trajectory has yet to propose. They believe their platform allows them to expand biological possibilities and generate proteins intractable to produce with other technologies to ensure the best drug candidates have the opportunity to become therapeutic realities for patients. Their goal is to enable the creation of better medicines by Translating Ideas into Drugs.
Industry
Services - Commercial Physical & Biological Research
CEO CFO
Sean McClain Gregory Schiffman
Employees Founded
169 2011

Contacts

Address: 18105 Se Mill Plain Blvd Vancouver, Wa 98683

Telephone: (360) 949-1041

Web page: http://www.absci.com

IPO information

First Trade Date 7/22/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 12.5
Shares Revised (MM) 12.5
Expected offer amount (MM) $100
Realized offer amount(MM) $200

Financial Data (last reporting year)

Market Cap (MM) $1446.08
Revenues (MM) $5.27
Net Income (Loss) (MM) $-22.66

Voting

What do you think will happen with the ABSI share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: JP Morgan

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
JP Morgan/ Credit Suisse/ BofA Securities/ Cowen/ Stifel
CO-Managers

Sector: Healthcare

Tweets about $ABSI

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats